ChatGPT

Perplexity

Gemini

Claude

Grok

The Edwards clinical education app supports your learning objectives with educational resources focused on the ClearSight system, the FloTrac system, the Swan-Ganz catheter, the HemoSphere advanced mo

Edwards Learning Network is paired to mirror your Edwards Learning Network online learning portal experience. Brought to you by Edwards Lifesciences, this app provides learners access to their courses

Edwards Masters, a Professional Education platform for cardio-thoracic surgeons.

At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting cardiovascular disease

The Clinical Pathways Application allows Physicians to complete a questionnaire for valve type of their choice to help determine if their patient can potentially qualify for an Edwards clinical trial 

Pioneering breakthrough medical technologies that address unmet patient needs and transform the treatment of structural heart disease through continuous research and development.

Innovation

Maintaining the highest standards of quality, ethics, and regulatory compliance in all aspects of medical device development, manufacturing, and commercialization.

Integrity

Placing patients at the center of every decision, with a commitment to improving clinical outcomes and quality of life for people suffering from cardiovascular disease.

Patient Focus

Working closely with healthcare professionals, clinical researchers, and industry partners to advance the science of structural heart disease treatment.

Collaboration

Providing exceptional support to clinicians and healthcare institutions through education, training, and technical expertise to ensure optimal patient outcomes.

Service Excellence

Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. The company develops groundbreaking technologies to treat heart valve disease and monitor patients' cardiovascular systems.

Bernard J. Zovighian

Chief Executive Officer & Chairman of the Board

Scott B. Ullem

Corporate Vice President & Chief Financial Officer

Dr. Todd J. Brinton

Corporate Vice President, Advanced Technology & Chief Scientific Officer

Daveen Chopra

Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies and Surgical

Larry L. Wood

Corporate Vice President & Group President, TAVR and Surgical Structural Heart

Dr. Huimin Wang

Corporate Vice President, Japan, Asia and Pacific

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; and Singapore; and is building a new facility completed in 2021 in Limerick, Ireland.

https://en.wikipedia.org/wiki/Edwards_Lifesciences

The SAPIEN platform, including SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA, represents the gold standard in transcatheter aortic valve replacement. These balloon-expandable valves made of bovine pericardial tissue within a cobalt-chromium frame are delivered via catheter for minimally invasive treatment of aortic stenosis. The RESILIA tissue variant incorporates advanced anti-calcification technology for improved durability.

SAPIEN Family of Transcatheter Aortic Valves

The PASCAL Precision transcatheter edge-to-edge repair system treats mitral and tricuspid valve regurgitation through a minimally invasive catheter-based approach. This innovative technology allows cardiologists to repair leaking heart valves without open-heart surgery, offering new hope to patients who are not candidates for traditional surgery.

PASCAL Precision System

A surgical tissue valve featuring RESILIA tissue technology and VFit design for patients requiring traditional open-heart surgery. The INSPIRIS valve offers surgeons a proven surgical solution with enhanced tissue durability through advanced anti-calcification treatment.

INSPIRIS RESILIA Aortic Valve

The Cardioband systems provide transcatheter direct annuloplasty for mitral and tricuspid valve regurgitation. This catheter-delivered implant reshapes and reduces the valve annulus, addressing the root cause of many valve leakage problems.

Cardioband Mitral and Tricuspid Repair Systems

The world's first transcatheter mitral valve replacement system, expected to receive CE Mark in mid-2025. This groundbreaking technology will allow minimally invasive replacement of diseased mitral valves, opening treatment options for patients who currently have limited therapeutic choices.

SAPIEN M3 Transcatheter Mitral Valve

Through the acquisition of JenaValve Technology, Edwards gained access to the first anticipated approved therapy for aortic regurgitation (AR). FDA approval is expected in late 2025, addressing a deadly disease that impacts a significant and growing population and is largely untreated today.

JenaValve Trilogy Heart Valve System

Acquired through the Endotronix acquisition, Cordella is an FDA-approved implantable pulmonary artery pressure sensor that enables early, targeted therapeutic intervention for heart failure patients. A CMS national coverage determination is expected in early 2025.

Cordella Heart Failure Management System

Edwards Lifesciences announced full year 2024 revenue of $5.44 billion, representing 8.6% growth. Q4 2024 sales grew 9% to $1.39 billion with strength across all product groups, including 6% TAVR growth and 88% TMTT growth to $105 million. The company demonstrated strong profitability with net margins of 22.8% and announced record cash flow generation.

Edwards Lifesciences Reports Strong Q4 and Full Year 2024 Results

CEO Bernard Zovighian outlined the company's growth strategy, projecting 8-10% total company sales growth for 2025. Edwards enters 2025 as a pure-play structural heart company with major growth drivers in TAVR and TMTT. The company projects TAVR sales of $4.1-4.4 billion (5-7% growth) and TMTT sales of $500-530 million (50-60% growth). CE Mark for SAPIEN M3 remains on track for mid-2025.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Edwards announced that real-world data for the SAPIEN 3 Ultra RESILIA valve demonstrated continued excellent outcomes for patients. The valve, which incorporates Edwards' breakthrough RESILIA tissue technology with advanced anti-calcification treatment, is showing strong clinical performance in routine practice.

Edwards SAPIEN 3 Ultra RESILIA Valve Shows Excellent Real-World Outcomes

The U.S. Federal Trade Commission announced its intention to block Edwards' proposed $1.2 billion acquisition of JenaValve Technology, which would bring the first therapy for aortic regurgitation to market. Edwards disagrees with the FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from this deadly disease.

FTC Moves to Block Edwards Lifesciences' Acquisition of JenaValve Technology

Edwards announced an accelerated share repurchase agreement to buy back $500 million of common stock, bringing total share repurchases in fiscal 2025 to over $800 million. This demonstrates the company's confidence in its financial position and commitment to returning capital to shareholders.

Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase

Edwards announced agreements to acquire JenaValve Technology (pioneer in transcatheter treatment of aortic regurgitation) and Endotronix (leader in heart failure management solutions with FDA-approved Cordella sensor) for a combined $1.2 billion. Edwards anticipates FDA approval of JenaValve Trilogy in late 2025 and CMS coverage for Cordella in early 2025.

Edwards Lifesciences Expands Structural Heart Portfolio with Acquisitions of JenaValve and Endotronix

Edwards completed the sale of its Critical Care business unit to BD (Becton Dickinson) for $4.2 billion, transforming into a pure-play structural heart company. The divestiture allows Edwards to focus exclusively on its core competency in transcatheter and surgical heart valve therapies, streamlining operations and sharpening strategic focus.

Edwards Lifesciences Sells Critical Care Business to BD for $4.2 Billion

Edwards Lifesciences Dress Code

🟢 Breaking 🚨 Ullem Scott B., CVP, Chief Financial Officer, just made an open-market purchase in Edwards Lifesciences Corp ($EW), buying 13,000 shares at $59.26 per share — a total of $770,337.

🟢 Insider Buy Alert: Donald E. Bobo Jr Buys Edwards Lifesciences (EW)

TI en Edwards Lifesciences

Offer revoked from Edwards Lifesciences

Edwards Lifesciences upgraded by Wolfe Research with a new price target

Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences

Edwards Lifesciences to Present at Citi's 2026 Unplugged Medtech and Life Sciences Access Day

Edwards Lifesciences ($EW) Reports Strong Q4, Raises 2026 Outlook

Quantisnow

insiderData

biotech

Ticos_TI

jobs

SECWatch

Edwards Lifesciences Corp

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Miles Lowell Edwards, a retired engineer, partnered with Dr. Albert Starr to develop the first artificial heart valve, establishing the foundation for what would become Edwards Lifesciences.

Company Founded

Dr. Albert Starr successfully implanted the revolutionary Starr-Edwards mitral valve in a patient on September 21, 1960, marking a watershed moment in cardiac surgery and validating the company's technology.

First Successful Heart Valve Implant

Edwards Laboratories was acquired by Baxter International, becoming part of a larger healthcare conglomerate while continuing to focus on cardiovascular innovation.

Acquired by Baxter International

Edwards Lifesciences was spun off from Baxter International, becoming an independent publicly traded company focused exclusively on cardiovascular medical devices and critical care monitoring.

Spun Off from Baxter International as Independent Public Company

Edwards received CE Mark approval for the SAPIEN transcatheter aortic heart valve, launching the era of minimally invasive valve replacement and establishing the company as a pioneer in TAVR technology.

Launch of SAPIEN Transcatheter Heart Valve in Europe

The company established the Edwards Lifesciences Foundation to support programs for underserved people with heart valve disease, demonstrating commitment to global health equity.

Edwards Lifesciences Foundation Launched

Edwards completed the acquisition of Valtech Cardio for $340 million, gaining the Cardioband mitral valve repair system and expanding its TMTT portfolio.

Acquisition of Valtech Cardio

Edwards received FDA approval for SAPIEN 3 and SAPIEN 3 Ultra valves for low-risk patients, significantly expanding the addressable market for transcatheter valve replacement.

FDA Approval for Low-Risk TAVR Patients

Edwards expanded its presence in China's structural heart market through strategic acquisition, positioning for growth in the world's largest healthcare market.

Acquisition of JC Medical

Edwards introduced the SAPIEN 3 Ultra RESILIA valve following FDA approval, incorporating breakthrough RESILIA tissue technology with advanced anti-calcification treatment for improved durability.

Launch of SAPIEN 3 Ultra RESILIA Valve

Bernard Zovighian was appointed CEO and joined the Board of Directors, succeeding Mike Mussallem who led the company's transformation into a TAVR leader over nearly two decades.

Bernard Zovighian Becomes CEO

Edwards announced agreements to acquire JenaValve Technology and Endotronix for a combined $1.2 billion, expanding into aortic regurgitation treatment and heart failure management.

Major Acquisitions: JenaValve and Endotronix

Edwards sold its Critical Care business unit to BD (Becton Dickinson) for $4.2 billion, becoming a pure-play structural heart company focused exclusively on valve therapies.

Divestiture of Critical Care Business to BD

CEO Bernard Zovighian outlined strong growth projections for 2025, with TAVR sales expected to grow 5-7% and TMTT sales projected to surge 50-60%, reinforcing Edwards' market leadership.

Annual Investor Conference: 2025 Growth Strategy

Edwards anticipates mid-year CE Mark for SAPIEN M3 (first transcatheter mitral valve replacement system) and late-year FDA approval for JenaValve Trilogy (first approved therapy for aortic regurgitation).

Expected SAPIEN M3 CE Mark and JenaValve FDA Approval

For use with the engineering kits “Robotics: Smart Machines”, “Robotics: Smart Machines - Rovers & Vehicles Edition”, and “Robotics: Smart Machines - Tracks & Treads Edition” by Thames & Kosmos.

This

Dreamehome App is to manage Dreame Bot cleaning robots to do your home floor cleaning.

Through the App , you may not only access to advanced functions of your robot for your daily home floor cleaning

The Blue Alliance is a tool to help FIRST Robotics teams scout for, compete at, and relive competitions.

The Blue Alliance app is the easiest way to access all the great content on thebluealliance.co

Hermes Robotics is a San Francisco-based robotics company founded that provides autonomous street sweeping as a service by retro-fitting existing vehicles with autonomous technology. The YC W21 company achieved $1M in revenue in 2024 with a lean team of just 5 employees, raised $125K from Y Combinator plus additional bootstrap funding, and received an M&A offer in April 2025.

Edwards Lifesciences vs Hermes Robotics

Edwards Lifesciences

About

Hermes Robotics

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time